Chambers Michael Andrew 4
4 · Sarepta Therapeutics, Inc. · Filed Aug 20, 2024
Insider Transaction Report
Form 4
Chambers Michael Andrew
Director
Transactions
- Purchase
Common Stock
2024-08-16$133.07/sh+13,106$1,744,015→ 260,102 total(indirect: By Trust) - Purchase
Common Stock
2024-08-16$134.06/sh+18,284$2,451,153→ 278,386 total(indirect: By Trust) - Purchase
Common Stock
2024-08-16$134.66/sh+5,648$760,560→ 284,034 total(indirect: By Trust)
Holdings
- 8,277
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.